CEACAM5 and colorectal carcinoma: To our best knowledge, this is the first proof-of-concept using an anti-CEA scFv chemically conjugated with PLGA-PEG polymers for nano-chemotherapeutic applications, facilitating the delivery of a conventional drug to treat CRC.